UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 150

Sortiert nach

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

The New England journal of medicine, 2018-05, Vol.378 (18), p.1691-1703

2018

Volltextzugriff (PDF)

Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

The New England journal of medicine, 2019-04, Vol.380 (15), p.1408-1420

2019

Volltextzugriff (PDF)

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

The Lancet (British edition), 2008-12, Vol.372 (9656), p.2115-2123

2008

Volltextzugriff (PDF)

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease

Alzheimer's research & therapy, 2019-08, Vol.11 (1), p.68-68, Article 68

2019

Volltextzugriff (PDF)

Prenatal methylmercury exposure from ocean fish consumption in the Seychelles child development study

The Lancet (British edition), 2003-05, Vol.361 (9370), p.1686-1692

2003

Volltextzugriff (PDF)

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects

Antimicrobial Agents and Chemotherapy, 2008-12, Vol.52 (12), p.4228-4232

2008

Volltextzugriff (PDF)

Randomized, controlled trial of telcagepant over four migraine attacks

Cephalalgia, 2010-12, Vol.30 (12), p.1443-1457

2010

Volltextzugriff (PDF)

Lack of a Significant Drug Interaction between Raltegravir and Tenofovir

Antimicrobial Agents and Chemotherapy, 2008-09, Vol.52 (9), p.3253-3258

2008

Volltextzugriff (PDF)

Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir

Antimicrobial Agents and Chemotherapy, 2008-12, Vol.52 (12), p.4338-4343

2008

Volltextzugriff (PDF)

Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir

Antimicrobial Agents and Chemotherapy, 2009-07, Vol.53 (7), p.2752-2755

2009

Volltextzugriff (PDF)

Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics

Antimicrobial Agents and Chemotherapy, 2009-05, Vol.53 (5), p.1747-1752

2009

Volltextzugriff (PDF)

Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women

British journal of clinical pharmacology, 2011-04, Vol.71 (4), p.616-620

2011

Volltextzugriff (PDF)

Combining dependent P-values

Statistics & probability letters, 2002-11, Vol.60 (2), p.183-190

2002

Volltextzugriff (PDF)

Sexually Dimorphic Behavioral Responses to Prenatal Dioxin Exposure

Environmental health perspectives, 2002-03, Vol.110 (3), p.247-254

2002

Volltextzugriff (PDF)

Progression from Prodromal Alzheimer's Disease to Mild Alzheimer's Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions

Journal of Alzheimer's disease, 2023-01, Vol.92 (1), p.341

2023

Volltextzugriff (PDF)

BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain

Brain (London, England : 1878), 2020-12, Vol.143 (12), p.3816-3826

2020

Volltextzugriff (PDF)

Testing Equality of Means Under Order Restrictions Using Multiple Contrasts

Communications in statistics. Theory and methods, 2008-09, Vol.37 (19), p.3029-3039

2008

Volltextzugriff (PDF)

Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease

Alzheimer's & dementia, 2020-11, Vol.16 (11), p.1483-1492

2020

Volltextzugriff (PDF)

Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimer’s disease

Molecular imaging and biology, 2022-12, Vol.24 (6), p.862-873

2022

Volltextzugriff (PDF)

The Seychelles Child Development Study of methyl mercury from fish consumption: analysis of subscales from the Child Behaviour Checklist at age 107 months in the main cohort

Neurotoxicology (Park Forest South), 2020-12, Vol.81, p.331-338

2020

Volltextzugriff (PDF)

VERUBECESTAT DISEASE PROGRESSION MODELING FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER’S DISEASE: NO DOSE- AND EXPOSURE-DEPENDENCY IN CLINICAL ENDPOINTS

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P249-P250

2019

Volltextzugriff (PDF)

P1‐044: VERUBECESTAT DISEASE PROGRESSION MODELING FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE: NO DOSE‐ AND EXPOSURE‐DEPENDENCY IN CLINICAL ENDPOINTS

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_4), p.P249-P250

2019

Volltextzugriff (PDF)

P1‐042: NEUROFIBRILLARY TANGLE IMAGING WITH [18F]MK‐6240 IN APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE PATIENTS

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_4), p.P249-P249

2019

Volltextzugriff (PDF)

NEUROFIBRILLARY TANGLE IMAGING WITH [18F]MK-6240 IN APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER’S DISEASE PATIENTS

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P249-P249

2019

Volltextzugriff (PDF)

Evaluation of 18 F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimer's disease

Molecular imaging and biology, 2022-12, Vol.24 (6), p.862

2022

Volltextzugriff (PDF)

1 – 25 von 150

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(139)
Mit Volltextzugriff
(134)

Publikationsform

Sprache

Englisch
(149)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease

Prenatal methylmercury exposure from ocean fish consumption in the Seychelles child development study

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects

Randomized, controlled trial of telcagepant over four migraine attacks

Lack of a Significant Drug Interaction between Raltegravir and Tenofovir

Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir

Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir

Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics

Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women

Combining dependent P-values

Sexually Dimorphic Behavioral Responses to Prenatal Dioxin Exposure

Progression from Prodromal Alzheimer's Disease to Mild Alzheimer's Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions

BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain

Testing Equality of Means Under Order Restrictions Using Multiple Contrasts

Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease

Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimer’s disease

The Seychelles Child Development Study of methyl mercury from fish consumption: analysis of subscales from the Child Behaviour Checklist at age 107 months in the main cohort

VERUBECESTAT DISEASE PROGRESSION MODELING FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER’S DISEASE: NO DOSE- AND EXPOSURE-DEPENDENCY IN CLINICAL ENDPOINTS

P1‐044: VERUBECESTAT DISEASE PROGRESSION MODELING FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE: NO DOSE‐ AND EXPOSURE‐DEPENDENCY IN CLINICAL ENDPOINTS

P1‐042: NEUROFIBRILLARY TANGLE IMAGING WITH [18F]MK‐6240 IN APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE PATIENTS

NEUROFIBRILLARY TANGLE IMAGING WITH [18F]MK-6240 IN APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER’S DISEASE PATIENTS

Evaluation of 18 F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimer's disease

Suchergebnisse filtern